Gilead Sciences, Inc.
NEWS
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 29, 2020.
The U.S. Food and Drug Administration (FDA) approved Kite Pharma’s Tecartus (brexucabtagene autoleucel) for adults with relapsed or refractory mantle cell lymphoma (MCL). Kite is a Gilead Science company.
Everybody seems to be back to work after the U.S. 4th of July holiday. Here’s a look at last week’s clinical trial updates.
Gilead Sciences reported additional data from its Phase III SIMPLE-Severe trial and a real-world retrospective group of patients with severe COVID-19.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 10, 2020.
A study published in the journal Nature on July 1 suggests that there may be a new way to target an HIV protein called capsid, which was almost unmanageable in patients until now.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
Gilead Sciences set the price of the only approved treatment for COVID-19, remdesivir, at $390 per vial, which for most patients receiving a 5-day treatment using six vials, would come to $2,340 per patient.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 29, 2020.
JOBS
IN THE PRESS